3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Bile Duct Neoplasms
1
Interventions
Oxaliplatin
53
Cisplatin
52
Fluorouracil
50
Capecitabine
48
pembrolizumab
39
Leucovorin
31
Docetaxel
26
Trastuzumab
23
Paclitaxel
20
Irinotecan
20
Ramucirumab
13
Bevacizumab
12
Cetuximab
9
Radiotherapy
8
Surgical Procedures, Operative
7
S 1 (combination)
7
Nivolumab
7
Epirubicin
7
Carboplatin
6
olaparib
5
Platinum
5
Everolimus
5
Sunitinib
4
Mitomycin
4
trastuzumab deruxtecan
3
lenvatinib
3
epacadostat
3
bemarituzumab
3
apatinib
3
Saline Solution
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Stomach Neoplasms
×
derazantinib
×
Clear all
NCT04604132
2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2
Terminated
47 enrolled
22 charts